vancomycin has been researched along with Cholangitis, Sclerosing in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 15 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bozward, AG; Oo, YH; Osei-Bordom, D; Ronca, V | 1 |
| Callaghan, G; Holtmann, G; Jones, MP; Koloski, N; Morrison, M; Pakneeshan, S; Shah, A | 1 |
| Carbone, M; Cristoferi, L; Halma, JC | 1 |
| Arrivé, L; Assis, DN; Bergquist, A; Bowlus, CL; Deneau, M; Forman, L; Ilyas, SI; Lunsford, KE; Martinez, M; Sapisochin, G; Shroff, R; Tabibian, JH | 1 |
| Ali, AH; Alrabadi, L; Buness, CW; Cox, KL; Fischer, R; Goel, A; Holtmann, GJ; Kulkarni, SS; Lewindon, P; Lindor, KD; Ragnekar, AS; Shah, A; Shah, S; Taylor, AE; Wadsworth, S | 1 |
| Ahmed, T; Hashem, D; Kayal, M; Ungaro, RC | 1 |
| Al-Bawardy, B; Almomen, HS | 1 |
| Ali, AH; Alrabadi, L; Berquist, WE; Buness, CW; Carey, EJ; Cox, KL; Damman, J; Davies, Y; Hurwitz, M; Lemos, LM; Lindor, KD; Shah, SB; Stephen, M | 1 |
| Gutin, LS; Lam, AY; Nguyen, Y; Velayos, FS | 1 |
| Amir, AZ; Deneau, MR; DiGuglielmo, M; Draijer, LG; El-Matary, W; Furuya, KN; Gupta, N; Guthery, SL; Hochberg, JT; Horslen, S; Jensen, MK; Jonas, MM; Kerkar, N; Koot, BGP; Laborda, TJ; Lee, CK; Loomes, KM; Mack, C; Martinez, M; Miethke, A; Miloh, T; Mogul, D; Mohammad, S; Ovchinsky, N; Perito, ER; Rao, G; Ricciuto, A; Sathya, P; Schwarz, KB; Shah, U; Singh, R; Valentino, PL; Vitola, B; Zizzo, A | 1 |
| Ali, S; Charles, R; Inayat, F; Rahman, AU; Zahid, E | 1 |
| Ali, AH; Alrabadi, L; Buness, CW; Cox, KL; Johnson, KM; Lindor, KD; Miloh, T | 1 |
| Dong, J; Du, W; Han, W | 1 |
| Assis, DN; Levy, C | 1 |
| Alrabadi, L; Fischer, RT; Holtmann, GJ; Johnson, KM; Lewindon, P; Shah, A | 1 |
| Gow, P; Hey, P; Johnson, P; Lokan, J | 1 |
| Ali, AH; Buness, CW; Carey, EJ; Cox, KL; Damman, JL; Lindor, KD; Rodriguez, EA | 1 |
| Chapman, RW | 1 |
| Bismuth, M; Blanc, P; de Chambrun, GP; Desreumaux, P; Funakoshi, N; Gerard, R; Nachury, M; Navarro, F; Panaro, F; Pariente, B; Valats, JC | 1 |
| Balouch, F; Lewindon, PJ; Muir, R; Reilly, CR; Steward-Harrison, LC; Tan, LZ | 1 |
| Abidian, M; Charabaty, A; Dao, A; Lestrange, A; Mattar, M; Rangnekar, A | 1 |
| Dillon, JF; Paterson, JC | 1 |
| Azizi, Z; Ebrahimi-Daryani, N; Khalili, H; Nasiri-Toosi, M; Nouri-Taromlou, MK; Rahimpour, S | 1 |
| Abdullah, BA; Cox, KL; Cox, KM; Davies, YK; Safta, A; Terry, AB | 1 |
| Abarbanel, DN; Benavides, JA; Cox, K; Cox, KL; Davies, Y; Marlen, N; Nadeau, KC; Seki, SM | 1 |
| Jorgensen, RA; Keach, JC; Lindor, KD; Petz, JL; Tabibian, JH; Talwalkar, JA; Weeding, E | 1 |
| Cox, KL; Cox, KM | 1 |
2 review(s) available for vancomycin and Cholangitis, Sclerosing
| Article | Year |
|---|---|
Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy.
Topics: Antibodies, Monoclonal, Humanized; Bile Acids and Salts; Cholangitis, Sclerosing; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Humans; Immune Checkpoint Inhibitors; Inflammatory Bowel Diseases; Intestinal Mucosa; Liver; Liver Cirrhosis, Biliary; Receptors, Cytoplasmic and Nuclear; T-Lymphocytes, Regulatory; Vancomycin | 2021 |
Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.
Topics: Cholangitis, Sclerosing; Colitis, Ulcerative; Disease Progression; Humans; Inflammatory Bowel Diseases; Treatment Outcome; Vancomycin | 2018 |
4 trial(s) available for vancomycin and Cholangitis, Sclerosing
| Article | Year |
|---|---|
The Time is Ripe for a Randomized Controlled Trial of Oral Vancomycin in Primary Sclerosing Cholangitis.
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Colitis, Ulcerative; Humans; Vancomycin | 2023 |
Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis.
Topics: Adolescent; Adult; Alanine Transaminase; Anti-Bacterial Agents; Child; Cholangitis, Sclerosing; gamma-Glutamyltransferase; Humans; Male; Prospective Studies; Vancomycin | 2020 |
A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Anti-Bacterial Agents; Biomarkers; Blood Sedimentation; Cholagogues and Choleretics; Cholangitis, Sclerosing; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Humans; Iran; Liver Function Tests; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome; Ursodeoxycholic Acid; Vancomycin; Young Adult | 2016 |
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bilirubin; Biomarkers; Cholangitis, Sclerosing; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Vancomycin; Young Adult | 2013 |
21 other study(ies) available for vancomycin and Cholangitis, Sclerosing
| Article | Year |
|---|---|
How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?
Topics: Adult; Anti-Bacterial Agents; Cholangitis, Sclerosing; Cohort Studies; Colitis, Ulcerative; Female; Humans; Middle Aged; Prospective Studies; Retrospective Studies; Vancomycin; Vancomycin-Resistant Enterococci; Young Adult | 2022 |
Reply: Insurance should cover vancomycin for primary sclerosing cholangitis.
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Humans; Insurance; Vancomycin | 2023 |
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Humans; Insurance; Vancomycin | 2023 |
Besting the Biologics: Vancomycin Monotherapy for Ulcerative Colitis Management in Patients with Primary Sclerosing Cholangitis.
Topics: Biological Products; Cholangitis, Sclerosing; Colitis, Ulcerative; Humans; Vancomycin | 2023 |
Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation.
Topics: Cholangitis, Sclerosing; Colitis, Ulcerative; Endoscopy; Humans; Liver Transplantation; Vancomycin | 2023 |
Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients.
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Clostridioides difficile; Clostridium Infections; Colitis, Ulcerative; Colonoscopy; Female; Humans; Immunosuppressive Agents; Liver Transplantation; Recurrence; Vancomycin; Young Adult | 2020 |
Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.
Topics: Administration, Oral; Adolescent; Bilirubin; Child; Cholangitis, Sclerosing; Female; Humans; Male; Propensity Score; Retrospective Studies; Serum Albumin; Treatment Outcome; Ursodeoxycholic Acid; Vancomycin | 2021 |
The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation.
Topics: Biological Products; Cholangitis, Sclerosing; Colitis, Ulcerative; Humans; Liver Transplantation; Vancomycin | 2021 |
Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent.
Topics: Adolescent; Cholangitis, Sclerosing; Colitis, Ulcerative; Female; Humans; Intestinal Mucosa; Vancomycin; Young Adult | 2021 |
Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis.
Topics: Cholangitis, Sclerosing; Clostridium Infections; Dysbiosis; Humans; Inflammatory Bowel Diseases; Vancomycin | 2020 |
Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
Topics: Child; Cholagogues and Choleretics; Cholangitis, Sclerosing; Humans; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid; Vancomycin | 2021 |
Letter to the Editor: Oral Vancomycin Versus No Therapy for Pediatric Primary Sclerosing Cholangitis.
Topics: Child; Cholangitis, Sclerosing; Humans; Vancomycin | 2021 |
Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation.
Topics: Adult; Anti-Bacterial Agents; Azathioprine; Cholangitis, Sclerosing; Ciprofloxacin; Drug Therapy, Combination; Humans; Liver Function Tests; Liver Transplantation; Male; Postoperative Complications; Prednisolone; Recurrence; Treatment Outcome; Vancomycin | 2017 |
Editorial: vancomycin - a promising option for the treatment of primary sclerosing cholangitis?
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Humans; Vancomycin | 2018 |
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Cholangitis, Sclerosing; Colitis, Ulcerative; Female; Humans; Male; Remission Induction; Retreatment; Vancomycin; Young Adult | 2018 |
Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.
Topics: Child; Cholangitis, Sclerosing; Colitis; Colitis, Ulcerative; Gastrointestinal Microbiome; Humans; Vancomycin | 2019 |
Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Cholangitis, Sclerosing; Colitis, Ulcerative; Follow-Up Studies; Humans; Prognosis; Remission Induction; Retrospective Studies; Vancomycin | 2019 |
Commentary: vancomycin or metronidazole in patients with primary sclerosing cholangitis?
Topics: Anti-Bacterial Agents; Cholangitis, Sclerosing; Female; Humans; Male; Metronidazole; Vancomycin | 2013 |
Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; Anti-Bacterial Agents; Blood Sedimentation; Child; Child, Preschool; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Disease Progression; Female; gamma-Glutamyltransferase; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Male; Prospective Studies; Treatment Outcome; Vancomycin | 2008 |
Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.
Topics: Adolescent; Alanine Transaminase; Blood Cell Count; Child; Child, Preschool; Cholangitis, Sclerosing; Cytokines; Female; gamma-Glutamyltransferase; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Liver Function Tests; Longitudinal Studies; Male; T-Lymphocytes, Regulatory; Treatment Outcome; Vancomycin | 2013 |
Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Biopsy; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Vancomycin | 1998 |